PT  - JOURNAL ARTICLE
AU  - Jonathan J Passeri
AU  - Sammy Elmariah
AU  - Ke Xu
AU  - Ignacio Inglessis
AU  - Joshua N Baker
AU  - Maria Alu
AU  - Susheel Kodali
AU  - Martin B Leon
AU  - Lars G Svensson
AU  - Philippe Pibarot
AU  - William F Fearon
AU  - Ajay J Kirtane
AU  - Gus J Vlahakes
AU  - Igor F Palacios
AU  - Pamela S Douglas
AU  - on behalf of the PARTNER Investigators
TI  - Transcatheter aortic valve replacement and standard therapy in inoperable patients with aortic stenosis and low EF
AID  - 10.1136/heartjnl-2014-306737
DP  - 2015 Mar 15
TA  - Heart
PG  - 463--471
VI  - 101
IP  - 6
4099  - http://heart.bmj.com/content/101/6/463.short
4100  - http://heart.bmj.com/content/101/6/463.full
SO  - Heart2015 Mar 15; 101
AB  - Objectives The aims of this study were to evaluate the effect of left ventricular (LV) dysfunction on clinical outcomes after transcatheter aortic valve replacement (TAVR) and standard therapy for severe aortic stenosis (AS) and to assess LV ejection fraction (LVEF) recovery and its impact on subsequent clinical outcomes. Methods Cohort B of the Placement of AoRtic TraNscathetER Valves trial randomised 342 inoperable patients with severe AS to TAVR or standard therapy. We defined LV dysfunction as an LVEF <50% and LVEF improvement as an absolute increase in LVEF ≥10% at 30 days. Results Baseline LV dysfunction did not affect survival after TAVR but was associated with increased cardiac mortality at 1 year with standard therapy (59.3% vs 45.8% with normal LVEF; HR=1.71 (95% CI 1.08 to 2.71); p=0.02). In those with LV dysfunction, LVEF improvement occurred in 48.7% and 30.4% of TAVR and standard therapy patients, respectively (p=0.08), and was independently predicted by relative wall thickness and receipt of TAVR. LVEF improvement with standard therapy portended reduced all-cause mortality at 1 year (28.6% vs 65.6% without LVEF improvement; HR=0.32 (95% CI 0.11 to 0.93); p=0.03) but not at 2 years. Conclusions In inoperable patients with severe AS, mild-to-moderate LV dysfunction is associated with higher cardiac mortality with standard therapy but not TAVR. A subset of patients undergoing standard therapy with LV dysfunction demonstrates LVEF improvement and favourable 1-year but not 2-year survival. TAVR improves survival and should be considered the standard of care for inoperable patients with AS and LVEF >20%. Trial registration number ClinicalTrials.gov Unique Identifier #NCT00530894.